BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 22, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 1998

View Archived Issues

Biapenem: safe and tolerable antibiotic for elderly subjects

Read More

Characterization of MAb 18B7, a candidate for human studies

Read More

Absence of cardiodepressive effects with beraprost

Read More

Fentanyl delivery via SmartMist provides effective analgesia

Read More

L-Ornithine-L-aspartate: safe treatment for cirrhosis and chronic hepatic encephalopathy

Read More

WR-238605 effectively protects against malaria infection in volunteer study

Read More

MacroChem and American Home Products sign collaborative agreement

Read More

Cephalon and Medtronic renew ITB copromotion agreement

Read More

Regressin holds promise for a wide range of cancers, new data indicates

Read More

Theragyn phase III testing will begin in U.K.

Read More

Phase I/II trial data released for P&U protease inhibitor

Read More

Impaired glucose tolerance and diabetes mellitus in AIDS patients treated with protease inhibitors

Read More

COL-1492 can be used several times daily without safety concerns

Read More

PRO-2000 prevents infection by STD pathogens other than HIV

Read More

Preclinical and clinical profile of (+)-calanolide A, a novel NNRTI from a natural source

Read More

Genome Therapeutics establishes licensing agreement with Princeton University

Read More

Addition of Remune to HAART leads to enhanced viral suppression

Read More

WF10, a unique AIDS treatment alternative evaluated in the clinic

Read More

Collagenase inhibitors in the pipeline at British Biotech

Read More

Merck's new tachykinin receptor antagonists useful for pain, inflammation, etc.

Read More

Subtype-selective MMP inhibitors patented by Agouron, Syntex

Read More

Antagonists of neurotrophin activity described by Allelix for pain, epilepsy and AD

Read More

New thrombin inhibitors synthesized at Merck & Co.

Read More

M-16049 compared to troglitazone for ability to improve insulin resistance

Read More

Effects of KRP-297 on progression of diabetes in db/db mice

Read More

Effects of new SGLT inhibitor on insulin and glucose in Zucker diabetic fatty rats

Read More

Aldose reductase inhibitor from Nippon Zoki effective in rats with diabetic neuropathy

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing